DUBLIN–(BUSINESS WIRE)–The “Novel Antibody Therapies Market: Distribution by Type of Novel Antibody, Target Indication, Type of Therapy, Route of Administration, and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035” report has been added to ResearchAndMarkets.com’s offering.
The ‘Novel Antibody Therapies Market, 2022-2035’ report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution of the novel antibody therapies in the treatment of various diseases.
The study presents an in-depth analysis, highlighting the diverse capabilities of players engaged in this domain, across different geographies.
One of the key objectives of the report was to identify the primary growth drivers and estimate the future growth opportunity associated with novel antibody therapies market in the mid to long term. Based on parameters, such as historical sales, target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the likely evolution of the market for the period 2022-2035.
Our year wise projections of the current and forecasted opportunity within the novel antibody therapies market have further been segmented across type of novel antibody (immunocytokines, immunotoxins, and radioisotope immunoconjugates), target indication (acute myeloid leukemia, bladder cancer, diffuse large b-cell lymphoma, graft-versus-host disease, melanoma prostate cancer, and soft-tissue sarcoma), type of therapy (Combination Therapy and Monotherapy), route of administration (intratumoral, intravenous and intravesical), key geographical regions (North America, Europe and Asia-Pacific).
In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
Amidst the recent initiatives undertaken to develop more targeted anti-cancer therapies, novel antibody therapies have emerged to be one of the most suitable option, having demonstrated the capability to selectively target and eliminate tumor cells. The novel antibody therapies include different classes of antibodies, which are capable of killing or inhibiting disease-causing agents.
Multiple antibody formats have been engineered to enhance therapeutic efficacy and target proteins that are expressed on the surface of the affected cells. This has opened a new target space for the development of antibody therapeutics and techniques, facilitating tools to uniquely distinguish malignantly transformed cells from regular cells. Various novel antibody therapies such as immuocytokines, immunotoxins, radioimmunoconjugates and intrabodies are being investigated as a therapeutic modality across multiple clinical trials, particularly as anti-cancer agents.
Till date, six novel antibody therapies, including Adcetris (mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, T-cell lymphoma and Hodgkin’s disease), Elzonris (Blastic plasmacytoid dendritic cell neoplasm) Lumoxiti (Hairy cell leukemia), PluvictoT (Prostate cancer), VicineumT (Bladder cancer) and Zevalin (Lymphoma) have so far been evaluated and approved for various oncological disorders.
In addition, more than 130 novel antibody therapies are being evaluated in various preclinical and clinical stages. Currently, more than 50 companies and academic / research institutes are engaged in the development of novel antibody therapies with enhanced efficacy and several promising leads are anticipated to be commercially launched over the coming decade.
Over 4,500 patents related to novel antibodies have been recently filed / granted, demonstrating the innovation and continuous research efforts in this domain. In addition, multiple collaborations have been inked between industry / academic stakeholders to advance the development of various pipeline molecules.
Moreover, with the active involvement of big pharma players as well as new entrants, the development pipeline of the novel antibody therapies is likely to expand further. Driven by the growing interest of various stakeholders and encouraging clinical research results, the novel antibody therapies market is anticipated to witness steady growth over the coming years.
Key Questions Answered
Who are the leading industry and non-industry players engaged in the development of novel antibody therapies?
Which novel antibody therapies are being developed across early and late stages of development?
Which geographies are the most active in conducting clinical trials related to novel antibody therapies?
What is the focus area of various publications related to the novel antibody therapies?
Which are the leading funding institutes / centers supporting the research related to novel antibody therapies?
What kind of partnership models are commonly adopted by industry stakeholders?
What are the different initiatives undertaken by big pharma players for the development of novel antibody therapies in the recent past?
How is the current and future market opportunity, related to novel antibody therapies likely to be distributed across key market segments?
Key Topics Covered:
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Overview of Novel Antibody Therapies
3.2. Types of Novel Antibody Therapies
3.3. Therapeutic Antibodies: Development Approaches
3.4. Future Perspectives
4. NOVEL ANTIBODY THERAPIES: MARKET LANDSCAPE
4.1. Analysis Methodology and Key Parameters
4.2. Novel Antibody Therapies: Development Pipeline (Immunocytokines)
4.3. Novel Antibody Therapies: Development Pipeline (Immunotoxins)
4.4. Novel Antibody Therapies: Development Pipeline (Radioisotope Immunoconjugates)
4.5. Novel Antibody Therapies: Development Pipeline (Other Antibodies)
4.6. Novel Antibody Therapies: List of Developers
5. COMPANY PROFILES
5.1. Actinium Pharmaceuticals
5.2. Molecular Templates
5.3. Philogen
5.4. Roche
5.5. Seagen
5.6. Sesen bio
5.7. Telix Pharmaceuticals
5.8. Y-mAbs Therapeutics
6. CLINICAL TRIAL ANALYSIS
6.1. Analysis Methodology and Key Parameters
6.2. List of Clinical Trials Focused on Novel Antibody Therapies
7. PUBLICATION ANALYSIS
7.1. Analysis Methodology and Key Parameters
7.2. List of Publications Focused on Novel Antibody Therapies
8. PATENT ANALYSIS
8.1. Analysis Methodology and Key Parameters
8.2. List of Patents Focused on Novel Antibody Therapies
9. PARTNERSHIPS AND COLLABORATIONS
9.1. List of Partnerships and Collaborations Focused on Novel Antibody Therapies
10. BIG PHARMA PLAYERS
10.1 Analysis Methodology and Key Parameters
10.2. Scoring Criteria for Key Parameters
10.3. List of Big Pharma Players Focused on Novel Antibody Therapies
11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Forecast Methodology and Key Assumptions
11.2. Global Novel Antibody Therapies Market, 2022-2035
11.3. Product-wise Sales Forecast (Marketed Drugs)
11.4. Global Novel Antibody Therapies Market, 2024 and 2035: Distribution by Type of Novel Antibodies
11.5. Global Novel Antibody Therapies Market, 2026 and 2035: Distribution by Target Disease Indication(s)
11.6. Global Novel Antibody Therapies Market, 2024 and 2035: Distribution by Type of Therapy
11.7. Global Novel Antibody Therapies Market, 2023 and 2035: Distribution by Route of Administration
11.8. Global Novel Antibody Therapies Market, 2024 and 2035: Distribution by Geography
11.9. Product-wise Sales Forecast (Phase III Drugs)
11.9.1. Adcetris (Seagen)
11.9.2. Fibromun (Philogen)
11.9.3. Iomab-B (Actinium Pharmaceuticals)
11.9.4. Nidlegy (Philogen)
11.9.5. T-Guard (Xenikos)
11.9.6. TLX 591 (Telix Pharmaceuticals)
11.9.7. Vicinium (Sesen Bio)
Companies Mentioned
3P Biopharmaceuticals
Aachen University Hospital
Actinium Pharmaceuticals
Active Biotech
Adium
Alkido Pharma
Ajinomoto Bio-Pharma
Albert Einstein College of Medicine
Alopexx Oncology
Angimmune
APEIRON Biologics
Astellas Pharma
AstraZeneca
atbtherapeutics
Atonco
AVEO Oncology
Avid Bioservices
Bayer
Beijing Shenogen Pharmaceutical
Biogen
Blood and Marrow Transplant Clinical Trials Network (BMT CTN)
Bright Peak Therapeutics
Bristol Myers Squibb
Cardinal Health
City of Hope Medical Center
Dana-Farber Cancer Institute
Duke University
Eastern Hepatobiliary Surgery Hospital (EHBH)
Eckert & Ziegler
Eczacibasi-Monrol
Eli Lilly
EMD Serono
EpicentRx
Eureka Therapeutics
Evergreen Theragnostics
Fred Hutchinson Cancer Research Center
FUJIFILM Pharmaceuticals U.S.A.
Fusion Pharmaceuticals
Genentech
GenesisCare
Genmab
Geno Pharmaceuticals
Gilead Sciences
Global Medical Solutions
Grand Pharmaceutical
Great Ormond Street Hospital for Children NHS Foundation Trust
GT Biopharma
Heidelberg University Hospital
Hikma Pharmaceuticals
iBio
Idec Pharmaceuticals (merged with Biogen)
Immatics Biotechnologies
Immedica Pharma
Immunomedics
Innate Pharma
InterX
IONETIX
Iovance Biotherapeutics
ITM Isotope Technologies Munich
Janssen Research & Development
Kanaph Therapeutics
Kettering Health
King’s College London
LifeArc
Livzon MABPharm
Ludwig Institute for Cancer Research
M.D. Anderson Cancer Center
Massachusetts General Hospital
Massachusetts Institute of Technology (MIT)
McMaster University
Memorial Sloan Kettering Cancer Center
Menarini Group
Merck
Molecular Templates
Nammi Therapeutics
NanoMab
National Cancer Institute (NCI)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Health and Medical Research (INSERM)
National Institutes of Health Clinical Center (NIHCC)
NIOWAVE
Nippon Shinyaku
Nordic Nanovector
NorthStar Medical Radioisotopes
Novartis
OncoBeta
OncoTherapy Science
Orano Med
Oslo University Hospital
Pfizer
Philogen
POINT Biopharma Global
Precirix
ProMIS Neurosciences
Qilu Pharmaceutical
Radiopharm Theranostics
Recepta Biopharma
Roche
Romagnolo Institute for the Study of Tumors “Dino Amadori”
Sanofi
SciClone Pharmaceuticals
Scripps Research
Seagen
Sesen Bio
SHINE Technologies
Stemline Therapeutics
Swixx BioPharma
Takeda
Telix Pharmaceuticals
TRIUMF
University of California
University of Pennsylvania
University of Southampton
University of Texas
USHEALTH
Vanderbilt University
Vertex Pharmaceuticals
Vybion
Xenikos
Y-mAbs Therapeutics
For more information about this report visit https://www.researchandmarkets.com/r/tlk983
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
